Shield Therapeutics plc
STX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £24,441 | £48,410 | £16,440 | £90,962 |
| - Cash | £5,608 | £13,948 | £2,821 | £12,117 |
| + Debt | £21,056 | £20,245 | £6,097 | £156 |
| Enterprise Value | £39,888 | £54,707 | £19,716 | £79,001 |
| Revenue | £25,184 | £13,085 | £5,499 | £1,519 |
| % Growth | 92.5% | 138% | 262% | – |
| Gross Profit | £10,569 | £4,027 | £1,997 | £539 |
| % Margin | 42% | 30.8% | 36.3% | 35.5% |
| EBITDA | -£16,577 | -£30,288 | -£46,067 | -£17,692 |
| % Margin | -65.8% | -231.5% | -837.7% | -1,164.7% |
| Net Income | -£21,272 | -£33,293 | -£40,444 | -£19,336 |
| % Margin | -84.5% | -254.4% | -735.5% | -1,272.9% |
| EPS Diluted | -0.024 | -0.037 | -0.17 | -0.095 |
| % Growth | 36.7% | 78.2% | -79.7% | – |
| Operating Cash Flow | -£7,007 | -£37,126 | -£18,247 | -£16,738 |
| Capital Expenditures | -£27 | -£2,948 | -£1,895 | -£2,064 |
| Free Cash Flow | -£7,034 | -£40,074 | -£20,142 | -£18,802 |